United Therapeutics CORP Form 4 insider transactions

United Therapeutics' President and COO, Michael Benkowitz, executed stock options and sold shares on December 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel at United Therapeutics, executed a pre-arranged transaction involving share tracking awards, resulting in a change in his beneficial ownership.

Director Louis W. Sullivan exercised stock options and sold shares of United Therapeutics Corp. on December 18, 2024, according to a recent SEC filing.

United Therapeutics' President and COO, Michael Benkowitz, executed stock options and sold shares on December 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, executed stock options and sold shares on December 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel at United Therapeutics, exercised share tracking awards and sold the underlying shares on December 5, 2024, according to a recent SEC filing.

United Therapeutics' President and COO, Michael Benkowitz, executed stock options and sold shares on December 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan on November 25, 2024.

Paul A. Mahon, EVP & General Counsel at United Therapeutics, executed a pre-arranged 10b5-1 plan involving the exercise of share tracking awards and subsequent sale of common stock.

United Therapeutics' President and COO, Michael Benkowitz, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on November 11, 2024, according to a pre-arranged Rule 10b5-1 trading plan.

Judy D. Olian, a director of United Therapeutics Corp, sold 1,750 shares of common stock at a price of $412.48 on November 11, 2024.

Nilda Mesa, a director at United Therapeutics Corp, sold 224 shares of common stock at a price of $412.278 per share on November 8, 2024.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised share tracking awards on November 7, 2024, according to a Form 4 filing.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock through a trust, according to a recent SEC Form 4 filing.

Director Richard Giltner exercised stock options and sold shares of United Therapeutics Corp on November 5, 2024.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Christopher Causey of United Therapeutics Corporation sold 510 shares of common stock on November 1, 2024, at a price of $376.6281 per share.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold a portion of the acquired shares on November 1, 2024.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on October 21, 2024, according to a Form 4 filing with the SEC.

Paul Mahon, EVP & General Counsel of United Therapeutics, executed share tracking award exercises on October 3 and October 17, 2024, according to a Form 4 filing.

James Edgemond, CFO of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond, CFO of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond, CFO of United Therapeutics, exercised stock options and sold shares of common stock on September 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond, CFO of United Therapeutics, exercised stock options and sold shares of common stock on September 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised share tracking awards for 7,700 shares under a pre-arranged 10b5-1 plan.

Director Judy D. Olian reports the acquisition and disposition of United Therapeutics Corp (UTHR) common stock and stock options on September 17, 2024.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond, CFO of United Therapeutics, exercised stock options and sold shares of common stock on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.